Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

53.40 -0.52 (-0.96%)
Streaming Delayed Price Updated: 11:54 AM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Via ACCESS Newswire
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Via ACCESS Newswire
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
Via ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESS Newswire
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Via ACCESS Newswire
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Via ACCESS Newswire
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Via ACCESS Newswire
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Via ACCESS Newswire
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Via ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Via ACCESSWIRE
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Via ACCESSWIRE
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Via ACCESSWIRE
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Via ACCESSWIRE
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Via ACCESSWIRE
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
Via ACCESSWIRE
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Via ACCESSWIRE
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.